A Multi-center, Open-label Study to Investigate the Efficacy and Safety of CDP870 in Active Crohn's Disease Patients, Who Showed no Clinical Efficacy in a Remission Induction Study (Study C87037) But Showed Clinical Efficacy After Additional Remission Induction Therapy Was Applied, at Week 26 After Subcutaneous Administration of CDP870 400 mg From Week 8 Until Week 24 at 4-week Intervals

Trial Profile

A Multi-center, Open-label Study to Investigate the Efficacy and Safety of CDP870 in Active Crohn's Disease Patients, Who Showed no Clinical Efficacy in a Remission Induction Study (Study C87037) But Showed Clinical Efficacy After Additional Remission Induction Therapy Was Applied, at Week 26 After Subcutaneous Administration of CDP870 400 mg From Week 8 Until Week 24 at 4-week Intervals

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Nov 2017

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Sponsors UCB
  • Most Recent Events

    • 12 Nov 2017 Outcomes of a population pharmacokinetic model assessing exposure-response relationship of of certolizumab pegol using pooled data from nine clinical trials of certolizumab pegol induction and maintenance therapy in patients with Crohns disease, including C87005,C87031,C87032, C87037, C87042, C87043,C87047, C87048 and C87085, published in the Alimentary Pharmacology and Therapeutics Journal.
    • 10 Jun 2017 Biomarkers information updated
    • 10 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top